Investigational drug · Phase 3
PD-1 inhibitor
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
5 still active
All registered trials
1,424
Any phase or sponsor naming "PD-1 inhibitor"
First trial start
2018
Feb 15, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PD-1 inhibitor", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Gastric or Gastroesophageal Junction Adenocarcinoma
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Colorectal Cancer
- Advanced Hepatocellular Carcinoma (HCC)
- GC/GEJC
- Neoplasms, Colorectal
- Solid Tumor
- Colon Cancer
- Rectal Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PD-1 inhibitor" as an intervention, largest first.
Groupe Hospitalier Pitie-SalpetriereAcademic, hospital or other
NCT04294771 · 500,000 participants (planned) · Start Jan 1, 2019 · Primary completion Jan 1, 2030
Drug: ICI · For: Myocarditis; Cardiomyopathies; Heart Diseases and 3 more
Sites: Paris, France
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT07036016 · 67,818 participants · Start Jan 1, 2015 · Primary completion Dec 31, 2024
Drug: EGFR-TKI; PD-1/PD-L1 inhibitor and 1 more · For: Non-Small Cell Lung Cancer (NSCLC)
- Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant ImmunotherapyActive, not recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07256002 · 10,000 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 1, 2023
Drug: PD-1 Inhibitors; Chemotherapy and 1 more · For: Lung Cancer (NSCLC)
Sites: Beijing, China
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
Quanli GaoGovernment (non-federal)
NCT06693440 · 3,000 participants (planned) · Start Jul 1, 2021 · Primary completion Nov 13, 2027
Drug: PD-1 Inhibitors · For: Efficacy, Team; Adverse Event
Sites: Zhengzhou, China
Johns Hopkins UniversityAcademic, hospital or other
NCT04898751 · 2,214 participants · Start Jan 1, 2008 · Primary completion Aug 31, 2020
Drug: Immune checkpoint inhibitor (ICI) · For: Cutaneous Toxicity From ICI Therapy
Sites: Baltimore, Maryland
Tongji HospitalAcademic, hospital or other
NCT05420922 · 2,000 participants (planned) · Start Nov 1, 2021 · Primary completion Aug 30, 2022
Drug: Lenvatinib Oral Product; PD-1 inhibitor · For: Hepatocellular Carcinoma; Programmed Cell Death 1; Effects of Immunotherapy
Sites: Wuhan, China
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)Recruiting
Qun ZhaoAcademic, hospital or other
NCT07401199 · 2,000 participants (planned) · Start Feb 5, 2026 · Primary completion Dec 30, 2027
Drug: Standard of Care PD-1 Inhibitors · For: Gastric Cancer (GC); Locally Advanced Gastric Cancer
Sites: Fuyang, China; Cangzhou, China; Hengshui, China · 9 sites in all
SWOG Cancer Research NetworkResearch network
NCT02154490 · 1,864 participants · Start Jul 8, 2014 · Primary completion Apr 1, 2022
Drug: Docetaxel; Durvalumab and 9 more · For: Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7
Sites: Birmingham, Alabama; Anchorage, Alaska; Fairbanks, Alaska · 1,004 sites in all
CCTU- Cancer ThemeAcademic, hospital or other
NCT04107168 · 1,800 participants (planned) · Start Jul 8, 2020 · Primary completion Jul 8, 2024
Drug: Nivolumab; Pembrolizumab and 5 more · For: Melanoma; Renal Cancer; Lung Cancer
Sites: Bath, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Application of Low-Dose Radiotherapy Combined with Immunotherapy for Drug-Resistant Hepatic Metastasis: a Case Series Analysis.
Liang G, Lyu B, Geng C, et al. · Clin Transl Radiat Oncol 2027
- Pembrolizumab-related tattoo sarcoidosis in a patient with breast cancer.
Wong JH, Pandey S, Tarricone G, et al. · JAAD Case Rep 2026
- CD73 targeted combination therapy reverses PD-1 inhibitor resistance in CD73-high PD-L1-negative NSCLC: Evidence from pleural effusion organoids.
Ren ZR, Wu L, Huang QL, et al. · Glob Med Genet 2026
- PiRNA-Hsap_1847317 may serve as a novel biomarker of PD-1 inhibitor resistance in patients with advanced non-small cell lung cancer.
Meng M, Yu B, Luo J, et al. · Transl Oncol 2026
- AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer.
Wan W, Wei F, Yang L, et al. · Biochem Pharmacol 2026
- CASPR2 antibody-associated neurological syndrome after PD-1 inhibitor treatment (tislelizumab) in a patient with lung adenocarcinoma: A case report and literature review.
Zhang L, Tai X, Zhao X, et al. · J Neuroimmunol 2026
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- AumolertinibSHR-A2009, HS-10296Phase 37 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.